AusperBio, a biotechnology company focused on curing chronic hepatitis B, has announced it raised $63 million in Series B2 funding. This new investment adds to the strong financial backing the company has already received and reflects growing confidence in its approach to treating one of the world’s most persistent viral diseases.
The funding round was co-led by Qiming Venture Partners and a globally recognized strategic investor. Several existing backers also joined again, including HanKang Capital, CDH Investments, YuanBio Venture Capital, Sherpa Capital, and Genesis Capital. Their continued support highlights their belief in AusperBio’s mission and progress.
AusperBio is developing a targeted therapy called AHB-137, designed to help patients achieve a functional cure for chronic hepatitis B. The new funds will be used to move this drug forward through clinical trials, including a pivotal study and multiple Phase II combination trials. The company also plans to expand its testing globally, which could bring the treatment closer to approval in more countries.
Beyond AHB-137, the funding will help AusperBio grow its broader pipeline of drug candidates. It will support further development of its Med-Oligo ASO platform, which is the foundation for its targeted therapies. The company will also invest in scaling up manufacturing partnerships and preparing for long-term growth.
AusperBio remains privately held and in the clinical stage, meaning its treatments are still being tested in humans. But with this new round of funding, the company is well-positioned to make meaningful progress toward a cure that could improve the lives of millions living with chronic hepatitis B.
KEY QUOTES:
“We are grateful for the continued support of our investors, whose confidence reflects both the progress of our clinical programs and the promise of our Med-Oligo platform. This financing positions us to accelerate the pivotal development of AHB-137, expand our global clinical footprint, strengthen our platform and pipeline, and advance our long-term vision of delivering a functional cure for people living with chronic hepatitis B and beyond.”
Dr. Guofeng Cheng, co-founder and CEO of AusperBio
“AHB-137 is the first candidate from our Med-Oligo™ platform to reach pivotal development, and the data reinforce its potential as a backbone therapy for CHB. This financing will accelerate the development of our next generation combination therapy for CHB and support continued advancement of a pipeline of innovative targeted oligonucleotide therapeutics addressing a broad range of diseases with serious unmet medical need.”
Dr. Chris Yang, co-founder and CSO of AusperBio
“AusperBio is pioneering a differentiated approach to curing chronic hepatitis B. With the advancement of AHB-137 into the pivotal trial, the company is well positioned to address one of the most serious unmet needs in global health. We have great confidence in the AusperBio team and are proud to support them as they work to bring transformative therapies to patients worldwide.”
William Hu, Managing Partner of Qiming Venture Partners
